metadata toggle
Pharmacological particulars
Pharmacotherapeutic group: Intestinal antiinfectives; antibiotics; paromomycin. ATCvet code: QA07AA06.
Pharmacodynamic properties
Paromomycin belongs to the group of aminoglycoside antibiotics. Paromomycin changes the reading of messenger-RNA, which disrupts protein synthesis. The bactericidal activity of paromomycin is mainly attributed to its irreversible binding to ribosomes. Paromomycin has broad spectrum activity against numerous Gram-positive and Gram-negative bacteria, including E. coli.
Paromomycin acts in a concentration-dependant manner. Five mechanisms of resistance have been identified: changes of the ribosomes due to mutations, reduction of permeability of bacterial cell wall or active efflux, enzymatic modification of ribosomes and inactivation of aminoglycosides by enzymes. The first three resistance mechanisms arise from mutations of certain genes on bacterial chromosome. The fourth and fifth resistance mechanism only occurs following uptake of mobile genetic elements coding for resistance. Paromomycin selects for resistance and cross-resistances at high frequency against a variety of other aminoglycosides among intestinal bacteria.
Pharmacokinetic particulars
Following oral administration of paromomycin, hardly any absorption takes place and the molecule is eliminated unchanged via the faeces.
Environmental properties
The active ingredient paromomycin sulfate is persistent in the environment